Molecular pathology of pituitary adenomas

Journal of Neuro-Oncology

Volumn 54, Issue 2, 2001, Pages 111-119

  Lloyd, R V ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cyclin dependent kinase inhibitors; p16; p27; Pituitary

Indexed keywords

CORTICOTROPIN; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR; GROWTH HORMONE; PROLACTIN; PROTEIN P16; PROTEIN P27; RETINOBLASTOMA PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; THYROTROPIN;

ADENOHYPOPHYSIS; ADENOHYPOPHYSIS HYPOFUNCTION; CANCER GROWTH; CARCINOGENESIS; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; HYBRIDIZATION; HYPOPHYSIS ADENOMA; MOLECULAR DYNAMICS; NONHUMAN; ONCOGENE; ONCOGENE RAS; POSTNATAL DEVELOPMENT; REVIEW; TUMOR SUPPRESSOR GENE;

ADENOMA; ANIMALS; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENES; PITUITARY NEOPLASMS;

EID: 0035184708     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012940929072     Document Type: Review

References (70)

1. Multistep signaling requirements for pituitary organogenesis in vivo
2. The cytogenesis and pathogenesis of pituitary adenomas
3. Molecular pathogenesis of pituitary tumors
4. New pituitary oncogenes
5. Geneology of anterior pituitary gland: Tracing a family tree
6. The pan-pituitary activator of transcription factor Ptx1 (pituitary homeobox) acts in synergy with SF-1 and Pit-1 and is an upstream regulator of the Lim-homeodomain gene Lim3/Lhx3
7. Pituitary homeobox 2, a novel member of the bicoid-related family of homeobox genes is a potential regulator of anterior structure formation
8. Expression of Ptx1 in the adult rat pituitary glands and pituitary cell lines: Hormone-secreting cells and folliculo-stellate cells
9. The Ames dwarf gene df is required early in pituitary ontogeny for the extinction of Rpx transcription and initiation of lineage-specific cell proliferation
10. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia
11. Characterization of prophet of pit-1 gene expression in normal pituitary and pituitary adenomas in human
12. Clonal origin of pituitary adenomas
13. Clinically nonfunctioning pituitary tumors are monoclonal in origin
14. Two G protein oncogenes in human endocrine tumors
15. G protein oncogenes in pituitary tumors
16. Rare mutation of the Gs alpha-subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction - Primer introduced restriction analysis
17. Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients
18. The cyclic adenosine 3′5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas
19. Ras mutations in human prolactinomas and pituitary carcinomas
20. H-ras mutations in human pituitary carcinoma metastasis
21. Ras mutations in human pituitary tumors
22. Isolation and characterization of a pituitary tumor-transforming gene (PTTG)
23. Pituitary tumor transforming gene expression in human pituitary adenomas
24. Cyclins and cancer II C cyclin D and CDK inhibitors come of age
25. Mammalian GI cyclins
26. Analysis of cyclin-D1 (CCND1) allelic imbalance and over-expression in sporadic pituitary tumors
27. Cyclin D and cyclin E expression in normal and adenomatous pituitary
28. Expression of D-type cyclins in normal and neoplastic rat pituitary
29. Germ-line mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states
30. The MEN-1 gene is rarely down-regulated in pituitary adenomas
31. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors. Evidence for a chromosomal 13 tumor suppressor gene other than RB
32. Chromosome 13q deletion mapping in pituitary tumors: Infrequent loss of the retinoblastoma susceptibility gene (RB1) despite loss of RB1 protein in somatotrophinomas
33. p53 gene mutations in pituitary adenoma: Rare events
34. Molecular screening of pituitary adenomas for gene mutations and rearrangements
35. p53 expression in pituitary adenomas and carcinoma. Correlation with invasiveness and tumor growth fractions
36. Pituitary carcinoma. A clinicopathologic study of 15 cases
37. Purine binding factor (nm23) gene expression in pituitary tumors: Markers of adenoma invasiveness
38. Cancer cell cycles
39. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression
40. INK4a gene product in human pituitary tumors
41. Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation
42. Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with non-functional pituitary adenomas but not somatotrophinomas
43. Transfection of an inducible p16/CDKN2A construct mediated reversible growth inhibition and G1 arrest in the AtT 20 pituitary tumor cell line
44. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers
45. kip1 deficient mice
46. Kip1
47. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
48. Aberrant p27kip1 expression in endocrine and other tumors
49. Kip1 and other cell-cycle protein expression in normal and neoplastic endocrine tissues
50. DNA methylation regulates p27kip1 expression in rodent pituitary cell lines
51. Transforming growth factor-beta and p27 expression in pituitary cells
52. Prolactinomas in male and female patients: A comparative clinicopathologic study
53. Transforming growth factor-beta, transforming growth factor-beta receptor and p27Kip1 expression in nontumorous and neoplastic human pituitaries
54. Aberrant DNA methylation of cyclin D2 and p27 genes in rodent pituitary tumor cell lines correlates with specific gene expression
55. A human pituitary adenoma cell line proliferates and maintains some differentiated functions following expression of SV40 large T-antigen
56. kip1 in normal corticotroph cells, corticotroph tumors and malignant pituitary tumors
57. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
58. Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (cdk) inhibitor by cyclin E/Cdk2
59. kip1
60. Combinatorial control in ubiquitin-dependent proteolysis: Don't skp the F-box hypothesis
61. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
62. Degradation of the cyclin-dependent kinase inhibitor p27 is instigated by Jab1
63. kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis
64. Functional collaboration between different cyclin-dependent kinase inhibitors suppress tumor growth with distinct tissue specificity
65. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas. The deleted region involves markers outside the MTS1 and MTS2 gene
66. Comparative genomic hybridization analysis of nonfunctioning pituitary tumors
67. Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in pituitary adenomas by comparative genomic hybridization
68. Detection of chromosomal imbalances in growth hormone-secreting pituitary tumors by comparative genomic hybridization
69. Cytogenetic alterations in pituitary adenomas detected by comparative genomic hybridization
70. Interphase analysis of chromosome 11 in human pituitary somatotroph adenomas by direct fluorescence in situ hybridization